Cost-effectiveness analysis of oral chemotherapy in ambulatory care: The example of vinorelbine;Analyse coût-efficacité des chimiothérapies par voie orale en médecine de ville: Le cas de la vinorelbine

Journal d'Economie Medicale

Volumn 20, Issue 7-8, 2002, Pages 379-400

  Le Lay, K ^a   Riou Franca L ^a   Launois, R ^b  

^a REES France   (France)

^b UNIVERSITÉ PARIS 13   (France)

Author keywords

First line; Non small cell lung cancer; Primary care

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL;

ARTICLE; BLOOD TOXICITY; BLOOD TRANSFUSION; CALCULATION; CANCER COMBINATION CHEMOTHERAPY; CONSULTATION; COST EFFECTIVENESS ANALYSIS; DAY HOSPITAL; DIAGNOSIS RELATED GROUP; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; FEBRILE NEUTROPENIA; HEALTH CARE COST; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MEDICAL SPECIALIST; NAUSEA; NEUROTOXICITY; PRIMARY MEDICAL CARE; PROBABILITY; SURVIVAL TIME; VOMITING;

EID: 0036875124     PISSN: 02940736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. American Cancer Society. Lung cancer 1998 facts and figures. [Acessed 1999, Feb. 22] http://www.cancer.org/statistics/cff98/selectedcancers.htm
2. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non small cell lung cancer. J Clin Oncol 1997 Aug; 15:2996-3018.
3. Score Santé: Indicateurs des Observatoires Régionaux de Santé: http://www.fnors.org/Score/Index1.htm
4. Goodwin PJ, Shephferd FA. Economic issues in lung cancer: a review. J Clin Oncol 1998 Dec; 16(12):3900-12.
5. Sonneberg FA, Beck JR. Markov Models in Medical Decision Making: A practical guide. Medical Decision Making 1993;13;322-338.
6. Le Chevalier T, Randomized study of vinorelbine and cisplatin vs vindesine and cisplatin vs vinorelbine alone, in advanced non small cell lung cancer. Journal of Clinical Oncology 1994; 12(2):360-67.
7. Bokkel Huinink. Single agent gemcitabine: an active and better tolerated alternative to standard cisplatin based chemotherapy in locally advanced or metastatic non small cell lung cancer. Elsevier Science 1999;26:85-94.
8. Roszkowski K. A multicenter, randomized study of docetaxel plus best supportive care vs best supportive care in chemotherapy naive patients with metastatic or non resectable localized nonsmall cell lung cancer. Elsevier Science 2000; 27:145-157.
9. Millward MJ, Bishop JF, Friedlander M et al. Phase II trial of 3-hour infusion of paclitaxel in previously untreated patients with advanced non small cell lung cancer. J Clin Oncol 1996;14:142- 148.
10. Jassem J, Ramlau R, Karnicka-Mlodkowska H et al. A multicenter randomized phase II study vs. intravenous vinorelbine in advanced nonsmall-cell lung cancer patients. Annals of Oncology 2001;12:1375-1381.
11. Depierre A, Freyer G, Jassem J et al. Oral vinorelbine: Feasibility and safety profile. Annals of Oncology 2001;12:1677-1681.
12. Depierre, Vinorelbine vs vinorelbine plus cisplatin in advanced non small cell lung cancer Annals of Oncology 1994;5:7-42.
13. Crawford J. Randomized Trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non small cell lung cancer. Journal of Clinical Oncology 1996;14 (10):2774-2784.
14. Perng-Perng Reury. Gemcitabine vs the combination of cisplatin and etoposide in patients with inoperable non small cell lung cancer in phase II randomized study. Journal of Clinical Oncology 1997;15(5):2097-2102.
15. Anderson H, Cottier B, Nicolson M et al. Phase III study of gemcitabine versus best supportive care in advanced non small cell lung cancer. Lung cancer 1997(suppl.1);18:9 (abstract 24).
16. Gatzemeier U, Heckmayr M, Neuhass R et al. Phase II study with paclitaxel for the treatment of advanced inoperable non small cell lung cancer. Lung cancer 1995;12;suppl.2:S101-S106.
17. Gatzemeier U, Shepherd FA, Le Chevalier T et al. Activity of gemcitabine in patients with non small cell lung cancer: a multicentre extended phase II study. Eur J Cancer 1996;32A:243-248.
18. Ranson M, Davidson N, Nicolson M et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non small cell lung cancer. Journal of the National Cancer Institute 2000;92(13):1074-1080.
19. Launois R, Croutsche JJ, Mégnigbêto AC, Le Lay K. L'apport indispensable de 1'épidémiologie clinique aux modèles de Markov. Journal d'Économie Médicale, 1999;17(5):343-361.
20. Miller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Medical Decision Making 1994; 14: 52-58.
21. Beck RJ, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient Approximation of Life Expectancy (The DEALE). The American Journal of Medicine 1982;73:889-897.
22. Launois R. Un coût, des coûts, quels coûts? Journal d'Économie Médicale 1999;17(1).
23. Le Brun T, Bonneterre J. Rapport d'étude: Évaluation de la Navelbine® per os. CRESGE. Août 1997.
24. Vergnenègre A, Launois R, Smadja C, Taieb C. Évaluation économique comparée du coût d'administration d'une chimiothérapie de vinorelbine en milieu hospitalier versus au domicile du patient.
25. Foulquier JN, Laugier A, Touboul E, Viardot JP, Schwartz LH. Coût de la chimiothérapie et coût du transport. Bull Cancer Radiother 1996;83:170-171.
26. Launois R. Qu'est-ce que la régulation médicalisée. In: Évaluation et régulation SNIP. John Libbey Eurotext. Paris. 1993:7-24. Repris sous le même titre dans Journal d'économie médicale 1994;12:63-74. Repris dans Biomédecine 2000 Technique et Documentation - Lavoisier, 1995:19-3.
27. Launois R. Qu'est-ce que la régulation médicalisée. In: Évaluation et régulation SNIP. John Libbey Eurotext. Paris. 1993:7-24. Repris sous le même titre dans Journal d'économie médicale 1994;12:63-74. Repris dans Biomédecine 2000 Technique et Documentation - Lavoisier, 1995:19-3.
28. Launois R. Qu'est-ce que la régulation médicalisée. In: Évaluation et régulation SNIP. John Libbey Eurotext. Paris. 1993:7-24. Repris sous le même titre dans Journal d'économie médicale 1994;12:63-74. Repris dans Biomédecine 2000 Technique et Documentation - Lavoisier, 1995:19-3.
29. Launois R, Reboul-Marty J. Coût-efficacité marginal: un outil de l'économiste. Cardioscopies 1994;23:170-173.
30. Epstein Richard J. Does the breast cancer dollar make sense? Eur J Cancer 1992;28(2-3):486-492.
31. Goldman L. Cost awareness in medicine, In: Wilson J, Braunwald E et al. Harrisson's principles of internal medicine. New York, Mc Grauw-Hill, 1990:11-15.
32. Laupacis A, Feeny D, Detsky AS, et Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization: tentative guidelines for using clinical and economic evaluations. Can Med Assoc J, 1992;146(4):473-481.
33. Tengs OT, Adams ME, Pliskin JS et al. Five hundred life saving interventions and their cost-effectiveness. Analysis 1995;15(3):369-390.